Selected articles
Articles for label Prosecká Pavlína are displayed.. Show all articles
Clear cell renal carcinoma treated with cabozantinib in the METEOR study – case study
05/2017 MUDr. Jana Katolická, Ph.D., MUDr. Sabina Svobodová, MUDr. Jiří Vaniček, Ph.D., Mgr. Pavlína Prosecká
Targeted treatment is currently a standard therapeutic method for metastatic clear cell renal carcinoma. Cabozantinib is an oral tyrosine kinase inhibitor including MET, VEGFR, and AXL. In a randomized phase III METEOR study, prolongation of survival in patients following prior VEGFR treatment with tyrosine kinase inhibitors has been demonstrated.
ENTIRE ARTICLE
Targeted treatment is currently a standard therapeutic method for metastatic clear cell renal carcinoma. Cabozantinib is an oral tyrosine kinase inhibitor including MET, VEGFR, and AXL. In a randomized phase III METEOR study, prolongation of survival in patients following prior VEGFR treatment with tyrosine kinase inhibitors has been demonstrated.